Top pharma companies turn in differing performances
In the face of difficult market conditions AstraZeneca was the only big pharma company to increase its growth rate last year compared with 2000/01, according to Wood Mackenzie's newly published Executive Guide to the pharmaceutical sector.
In the face of difficult market conditions AstraZeneca was the only big pharma company to increase its growth rate last year compared with 2000/01, according to Wood Mackenzie's newly published Executive Guide to the pharmaceutical sector.
The report offers analysis of the current position of the top 20 big pharma companies and focuses on what Wood Mackenzie sees as the key issues facing each company going forward. AZ's increase in growth from 4.2% to 9.8% was attributed to increased sales of Losec/Prilosec, Nexium and Seroquel.
Amgen continues to invest heavily in r&d, with a spend equivalent to 22.4% of ethical drug sales, and is reaping the rewards as it moves to the top of the global growth rankings with growth of 42.2% year-on-year.
'In terms of the 2002 global rankings, there were a number of important moves among the top 20 companies,' comments Martyn Link, consultant at Wood Mackenzie. 'For example, 2002 saw Roche jump three places to 9th in the industry rankings according to ethical drug sales, largely due to a strong performance by its oncology division. Conversely, Bristol-Myers Squibb (BMS) fell one place to 8th, primarily due to the negative impact of generic competition to Glucophage, BuSpar and Taxol.'
The 2003 edition of the Executive's Guide contains global rankings of the top 20 pharma companies by sales, growth and r&d spend; and executive summaries of the top 20 pharma companies, including breakdown of sales by sector, geography and therapy area; an r&d overview and Wood Mackenzie insight into the key issues facing the company in the coming year.